Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients

Neoplasma

Volumn 56, Issue 3, 2009, Pages 275-278

  Zavodna, K ^a,b   Konecny, M ^a   Krivulcik, T ^b   Spanik, S ^a   Behulova, R ^c   Vizvaryova, M ^a   Weismanova, E ^a   Galbavy, S ^a   Kausitz, J ^a  

^a ST ELIZABETH CANCER INSTITUTE   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

^c Physics and Informatics   (Slovakia)

Author keywords

Colorectal cancer; Genetic analysis; KRAS mutation; Metastasis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; PARAFFIN;

ARTICLE; CANCER PATIENT; CARCINOGENESIS; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA ISOLATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; METASTASIS; ONCOGENE K RAS; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SOMATIC MUTATION; COLORECTAL TUMOR; GENETICS; MUTATION; ONCOGENE RAS; PATHOLOGY; POLYMERASE CHAIN REACTION;

COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; MUTATION; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION;

EID: 67650308948     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_03_275     Document Type: Article

References (21)

1. FEARON ER, VOGELSTEIN B. A genetic model for colorectal tumorigenesis. Cell 1990;61(5):759-67. doi:10.1016/ 0092-8674(90)90186-I
2. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7(4):295-308. doi:10.1038/nrc2109 (Pubitemid 46480970)
3. Bamford S, Dawson E, Forbes S et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004; 91(2):355-358. (Pubitemid 39037083)
4. Koshiba M, Ogawa K, Hamazaki S et al. The effect of formalin fixation on DNA and the extraction of high-molecular-weight DNA from fixed and embedded tissues. Pathol Res Pract 1993;189(1):66-72. (Pubitemid 23117652)
5. TSAO MS, SAKURADA A, CUTZ JC et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353(2):133-144. doi:10.1056/NEJMoa050736 (Pubitemid 41058345)
6. Do H, Krypuy M, MITCHELL PL et al. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008;8:142. doi:10.1186/147124078142 (Pubitemid 351785125)
7. Zavodna K, Bujalkova M, Krivulcik T et al. Novel and recurrent germline alterations in the MLH1 and MSH2 genes identified in hereditary nonpolyposis colorectal cancer patients in Slovakia. Neoplasma 2006;53(4):269-276. (Pubitemid 44105931)
8. Bartosova Z, Zavodna K, Krivulcik T et al. STK11/lKB1 germline mutations in the first Peutz-Jeghers syndrome patients identified in Slovakia. Neoplasma 2007;54(2):101-107.
9. Alemayehu A, Tomkova K, Zavodna K et al. The role of clinical criteria, genetic and epigenetic alterations in Lynch-syndrome diagnosis. Neoplasma 2007;54(5):391-401.
10. Konecny M, Zavodna K, Vranova V et al. Identification of rare complete BRCA1 gene deletion using a combination of SnP haplotype analysis, MLPA and array-CGH techniques. Breast Cancer Res Treat 2008;109(3):581-583. doi:10.1007/ s10549-007-9670-9680
11. Bujalkova M, Zavodna K, Krivulcik T et al. Multiplex SNa-Pshot Genotyping for detecting loss of Heterozygosity in the Mismatch-Repair Genes MLH1 and MSH2 in Microsa-tellite-Unstable Tumors. Clin Chem. 2008; 54(11):184454. doi:10.1373/clinchem.2008.108902
12. Benvenuti S, Frattini M, Arena S et al. PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat. 2008;29(2):284-288 doi:10.1002/humu.20648 (Pubitemid 351240601)
13. Krypuy M, NEWNHAM GM, THOMAS DM et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in nonsmall cell lung cancer. BMC cancer 2006;6:295. doi:10.1186/147124076295 (Pubitemid 46178886)
14. ROCK EP, KENNEDY DL, FURNESS MH et al. Patientreported outcomes supporting anticancer product approvals. J Clin Oncol 2007;25(32):5094-5099. doi:10.1200/ Jco.2007.11.3803
15. Esteller M, González S, RISQUES RA et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001;19(2):299-304. (Pubitemid 32112840)
16. Simi L, Pratesi N, Vignoli M et al. Highresolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008;130(2):247-253 doi:10.1309/LWDY1AXHXUULNVHQ
17. Di Fiore F, Charbonnier F, Lefebure B et al. Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer. Br J Cancer 2008;99(3):551-552. doi:10.1038/sj.bjc.6604451
18. Van Krieken J, Jung A, Kirchner T et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European Quality Assurance program. Virchows Arch 2008;453:417-431. doi:10.1007/ s00428-008-0665-y
19. DER CJ, FINKEL T, COOPER GM. Biological and biochemical properties of human rasH genes mutated at codon 61. Cell 1986;44(1):167-176. doi:10.1016/0092-8674(86)90495-2 (Pubitemid 16036724)
20. Adijei A. Blocking onkogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001;93:1062-1074. doi:10.1093/ jnci/93.14.1062
21. Bos J. Ras oncogens in human cancer: a review. Cancer Res. 1989;49:4682-4689. (Pubitemid 19213607)